Albireo Pharma (NASDAQ:ALBO) Rating Lowered to Hold at BidaskClub

Share on StockTwits

Albireo Pharma (NASDAQ:ALBO) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, BidAskClub reports.

Several other brokerages have also recently issued reports on ALBO. Zacks Investment Research raised shares of Albireo Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. Wedbush set a $69.00 price objective on shares of Albireo Pharma and gave the company a “buy” rating in a report on Thursday, May 23rd. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. William Blair reaffirmed an “outperform” rating on shares of Albireo Pharma in a report on Thursday, May 9th. Finally, Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a report on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $54.25.

Shares of Albireo Pharma stock opened at $32.39 on Monday. Albireo Pharma has a 1 year low of $19.10 and a 1 year high of $38.69. The firm has a market cap of $382.75 million, a P/E ratio of -8.22 and a beta of 1.66.

Albireo Pharma (NASDAQ:ALBO) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.37) by ($0.02). Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%. The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.20 million. As a group, analysts forecast that Albireo Pharma will post -5.99 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Private Advisors LLC increased its holdings in Albireo Pharma by 3.4% in the first quarter. Private Advisors LLC now owns 15,198 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 506 shares in the last quarter. Alps Advisors Inc. increased its holdings in Albireo Pharma by 4.5% in the first quarter. Alps Advisors Inc. now owns 28,912 shares of the biopharmaceutical company’s stock valued at $931,000 after buying an additional 1,253 shares in the last quarter. Prudential Financial Inc. increased its holdings in Albireo Pharma by 5.6% in the fourth quarter. Prudential Financial Inc. now owns 26,556 shares of the biopharmaceutical company’s stock valued at $652,000 after buying an additional 1,404 shares in the last quarter. Hartwell J M Limited Partnership increased its holdings in Albireo Pharma by 17.8% in the first quarter. Hartwell J M Limited Partnership now owns 14,250 shares of the biopharmaceutical company’s stock valued at $459,000 after buying an additional 2,150 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Albireo Pharma by 7.2% in the fourth quarter. Bank of New York Mellon Corp now owns 37,552 shares of the biopharmaceutical company’s stock valued at $921,000 after buying an additional 2,529 shares in the last quarter. 70.41% of the stock is owned by institutional investors.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Recommended Story: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amcor plc  Given $10.74 Average Target Price by Brokerages
Amcor plc Given $10.74 Average Target Price by Brokerages
Zacks: EP Energy Corporation  Given $1.21 Consensus Target Price by Analysts
Zacks: EP Energy Corporation Given $1.21 Consensus Target Price by Analysts
Brokerages Expect Stoke Therapeutics  to Post  Earnings Per Share
Brokerages Expect Stoke Therapeutics to Post Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV  to Post $0.29 Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV to Post $0.29 Earnings Per Share
Exelixis, Inc.  Expected to Announce Earnings of $0.25 Per Share
Exelixis, Inc. Expected to Announce Earnings of $0.25 Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp  to Announce $0.38 Earnings Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp to Announce $0.38 Earnings Per Share


© 2006-2019 Ticker Report